Alzheimer's Disease Cooperative Study (ADCS), NIH neurology news
NIH's National Institute on Aging awarded $11 million for FY13 to the ADCS consortium to support four clinical trials evaluating potential Alzheimer's disease treatments. The consortium said it is eligible to receive up to $55 million over a five-year period for the trials. One trial will evaluate an undisclosed amyloid-clearing therapeutic in pre-symptomatic patients. A second trial will track levels of AD-related proteins in cerebrospinal fluid (CSF) and plasma to help researchers understand how a therapeutic influences Alzheimer's pathology and to help guide decisions on whether a compound warrants further clinical testing. The consortium will also evaluate whether generic prazosin can be used to treat agitation in AD patients and whether supervised aerobic exercise can influence cognitive decline, slow brain atrophy or mitigate Alzheimer's pathology in adults with mild cognitive impairment (MCI)...